SB-228357
SB-228357 is a serotonin receptor agonist that was discovered and developed by SmithKline Beecham. It is a potent and selective 5-HT4 receptor agonist, with a pKi of 9.5, and has been used in scientific research to study the function of the 5-HT4 receptor.
History[edit | edit source]
SB-228357 was first discovered and developed by the pharmaceutical company SmithKline Beecham. The compound was identified as a potent and selective 5-HT4 receptor agonist, which made it a valuable tool in scientific research to study the function of the 5-HT4 receptor.
Pharmacology[edit | edit source]
SB-228357 is a potent and selective 5-HT4 receptor agonist. The 5-HT4 receptor is one of the several different subtypes of the serotonin receptor, which is a group of G protein-coupled receptors that are targeted by a variety of drugs used in the treatment of various disorders, including depression, anxiety, and migraine.
Research[edit | edit source]
SB-228357 has been used in scientific research to study the function of the 5-HT4 receptor. The compound's potent and selective agonist activity at the 5-HT4 receptor makes it a valuable tool in this research.
See also[edit | edit source]
SB-228357 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
References[edit | edit source]
External links[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD